{
  "docId": "019de076-4eee-72eb-9f75-bef42550a1c1",
  "docSlug": "3c2d586ebe2940705b3e5004470d76e3",
  "documentTitle": "Kymera | Investor Presentation Deck | 41 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 41,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4eee-72eb-9f75-bef42550a1c1/4",
  "deckHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1",
  "deckJsonHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1.json",
  "deckAnchorHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.536,
        "w": 0.844,
        "x": 0.128,
        "y": 0.264
      },
      "kind": "list",
      "text": "Dosed first patient in KT-474 Hidradenitis Suppurativa Phase 2 clinical trial; Initial patient dose generated first development milestone ($40M) from Sanofi. Demonstrated initial KT-333 anti-tumor activity in Phase 1 clinical trial; additional disclosure expected in poster at ASH 2023. Demonstrated proof-of-mechanism in KT-253 and initial antitumor activity in first patient cohort without typical MDM2 hematologic toxicity. Reprioritized pipeline, allocating resources and capital to emerging immunology pipeline. Extended cash runway into first half of 2026",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c601caa1-aa00-45c8-93e0-eb29735cab58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.342,
        "x": 0.329,
        "y": 0.045
      },
      "kind": "title",
      "text": "Recent Accomplishments",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa63687d-37ed-4fe4-b466-82107dcf2f31",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 3,
      "beatId": "09ac63a6-d365-4a05-bccb-492d1b9f90be",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The deck presents an overview of the current treatment landscape and unmet medical needs.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 4,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7b2f8e7d-1f1b-4a1d-b672-7e5ac94e5f10",
      "evidence": "The deck presents the limitations of current therapies and unmet medical needs.",
      "position": 0,
      "objective": "What are the consequences of not adopting Kymera's platform?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}